Gerd-Rüdiger Burmester spends much of his time researching Immunology, Rheumatoid arthritis, Internal medicine, Rheumatology and Tissue engineering. The Rheumatoid arthritis study combines topics in areas such as Intensive care medicine, Rheumatism, Disease and Arthritis. His research on Internal medicine frequently links to adjacent areas such as Surgery.
Gerd-Rüdiger Burmester has researched Surgery in several fields, including Odds ratio, Placebo and Logistic regression. The various areas that he examines in his Rheumatology study include Orthopedic surgery and Cohort study. Gerd-Rüdiger Burmester has included themes like Biomaterial, Chondrocyte, Matrix and Transplantation in his Tissue engineering study.
Immunology, Internal medicine, Rheumatoid arthritis, Arthritis and Rheumatology are his primary areas of study. His study in Autoantibody, Immune system, Antibody, Antigen and Inflammation is carried out as part of his Immunology studies. His studies examine the connections between Autoantibody and genetics, as well as such issues in Pathology, with regards to Chondrocyte.
In the field of Internal medicine, his study on Clinical trial overlaps with subjects such as In patient. Tocilizumab is closely connected to Adverse effect in his research, which is encompassed under the umbrella topic of Rheumatoid arthritis. As part of the same scientific family, Gerd-Rüdiger Burmester usually focuses on Endocrinology, concentrating on Peripheral blood mononuclear cell and intersecting with Glucocorticoid.
Gerd-Rüdiger Burmester spends much of his time researching Internal medicine, Immunology, Rheumatoid arthritis, Arthritis and In patient. In general Internal medicine, his work in Adverse effect, Rheumatology, Adalimumab and Clinical trial is often linked to Sarilumab linking many areas of study. His biological study spans a wide range of topics, including Methotrexate, Surgery and Combination therapy, Pharmacology.
Immunology is often connected to Lupus nephritis in his work. His Rheumatoid arthritis study combines topics from a wide range of disciplines, such as Factor XIII and Fibrinogen. The study incorporates disciplines such as Rituximab, Monoclonal, Mesenchymal stem cell, Cell biology and Lactate dehydrogenase A in addition to Arthritis.
Gerd-Rüdiger Burmester mainly investigates Internal medicine, Rheumatoid arthritis, Immunology, Rheumatology and Autoantibody. His Internal medicine research includes themes of Gastroenterology and Surgery. His work on Adalimumab and TNF inhibitor as part of general Rheumatoid arthritis study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His study in Peripheral blood mononuclear cell extends to Immunology with its themes. His Rheumatology research incorporates themes from Therapy management and Family medicine. His work in Autoantibody addresses subjects such as Antigen, which are connected to disciplines such as Antibody, Vimentin, Serology and Anti-dsDNA antibodies.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados.
Arthritis & Rheumatism (2006)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados.
Annals of the Rheumatic Diseases (2010)
Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging.
M. Backhaus;T. Kamradt;D. Sandrock;D. Loreck.
Arthritis & Rheumatism (1999)
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
Roy M. Fleischmann;Joy Schechtman;Ralph Bennett;Malcolm L. Handel.
Arthritis & Rheumatism (2003)
Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.
Jochen Ringe;Sandra Strassburg;Sandra Strassburg;Katja Neumann;Michaela Endres.
Journal of Cellular Biochemistry (2007)
Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action.
Frank Buttgereit;Rainer H Straub;Martin Wehling;Gerd-Rüdiger Burmester.
Arthritis & Rheumatism (2004)
Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints
M Backhaus;G R Burmester;D Sandrock;D Loreck.
Annals of the Rheumatic Diseases (2002)
Bioenergetics of immune functions: fundamental and therapeutic aspects
Frank Buttgereit;Gerd-Rüdiger Burmester;Martin D Brand.
Immunology Today (2000)
Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system.
Tobias Alexander;Andreas Thiel;Oliver Rosen;Gero Massenkeil.
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
J. Braun;J. Brandt;J. Listing;A. Zink.
Arthritis & Rheumatism (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: